Theranexus

Theranexus company information, Employees & Contact Information

Explore related pages

Related company profiles:

Theranexus is an innovative biopharmaceutical company that spun off from the French Alternative Energies and Atomic Energy Commission (CEA). It specializes in the treatment of rare central nervous system disorders and is a pioneer in the development of drug candidates targeting both neurons and glial cells. Theranexus has a unique advanced therapy candidate identification and characterization platform focused on rare neurological disorders and an initial drug candidate in clinical development for Batten disease.

Company Details

Employees
15
Founded
-
Address
60, Avenue Rockefeller, Lyon,auvergne-Rhône-Alpes 69008,france
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Lyon, Auvergne-Rhône-Alpes
Looking for a particular Theranexus employee's phone or email?

Theranexus Questions

News

Theranexus : THERANEXUS ANNOUNCES ITS CASH POSITION AS OF SEPTEMBER 30, 2024 - MarketScreener

Theranexus : THERANEXUS ANNOUNCES ITS CASH POSITION AS OF SEPTEMBER 30, 2024 MarketScreener

THX Pharma announces the launch of a capital increase with preferential subscription rights of nearly EUR 8… - Actusnews

THX Pharma announces the launch of a capital increase with preferential subscription rights of nearly EUR 8… Actusnews

Theranexus Presents an Update of its Cash Position and Financing Horizon - Yahoo Finance

Theranexus Presents an Update of its Cash Position and Financing Horizon Yahoo Finance

Theranexus : THX PHARMA (THERANEXUS) AND EXELTIS ACHIEVE KEY MILESTONE TOWARDS THE COMMERCIALIZATION OF TX01 - MarketScreener

Theranexus : THX PHARMA (THERANEXUS) AND EXELTIS ACHIEVE KEY MILESTONE TOWARDS THE COMMERCIALIZATION OF TX01 MarketScreener

Theranexus and Exeltis (Insud Pharma) Announce Licensing Agreement to Commercialize Theranexus Tx01 for Two Rare Neurological Disorders - Yahoo Finance

Theranexus and Exeltis (Insud Pharma) Announce Licensing Agreement to Commercialize Theranexus Tx01 for Two Rare Neurological Disorders Yahoo Finance

Theranexus Becomes THX Pharma: A Strategic Evolution Toward the Commercialization of Its Medicines for Rare… - Actusnews

Theranexus Becomes THX Pharma: A Strategic Evolution Toward the Commercialization of Its Medicines for Rare… Actusnews

THERANEXUS : PUBLISHES ITS CASH POSITION AS OF 30 JUNE 2025 - MarketScreener

THERANEXUS : PUBLISHES ITS CASH POSITION AS OF 30 JUNE 2025 MarketScreener

THERANEXUS AND BEYOND BATTEN DISEASE FOUNDATION ANNOUNCE STRONG POSITIVE REAL-WORLD DATA SUPPORTING BATTEN-1… - Actusnews

THERANEXUS AND BEYOND BATTEN DISEASE FOUNDATION ANNOUNCE STRONG POSITIVE REAL-WORLD DATA SUPPORTING BATTEN-1… Actusnews

Theranexus : THERANEXUS PUBLISHES ITS CASH POSITION AS OF 31 DECEMBER 2024 AND PRESENTS ITS PROGRESS REPORT - MarketScreener

Theranexus : THERANEXUS PUBLISHES ITS CASH POSITION AS OF 31 DECEMBER 2024 AND PRESENTS ITS PROGRESS REPORT MarketScreener

THERANEXUS ANNOUNCES FIRST HALF 2025 FINANCIAL RESULTS - Actusnews

THERANEXUS ANNOUNCES FIRST HALF 2025 FINANCIAL RESULTS Actusnews

THERANEXUS : ANNOUNCES ITS FINANCIAL CALENDAR FOR 2025 - MarketScreener

THERANEXUS : ANNOUNCES ITS FINANCIAL CALENDAR FOR 2025 MarketScreener

Update on the Theranexus' Batten-1 project in CLN3 Batten's disease - Actusnews

Update on the Theranexus' Batten-1 project in CLN3 Batten's disease Actusnews

Theranexus : THERANEXUS ANNOUNCES THE PUBLICATION OF ITS LETTER TO SHAREHOLDERS - MarketScreener

Theranexus : THERANEXUS ANNOUNCES THE PUBLICATION OF ITS LETTER TO SHAREHOLDERS MarketScreener

Theranexus raises around 3.1 million euros in fundraising - Actusnews

Theranexus raises around 3.1 million euros in fundraising Actusnews

Theranexus : publishes its cash position as of 30 June 2024 and presents an update on the progress of Batten-1 - MarketScreener

Theranexus : publishes its cash position as of 30 June 2024 and presents an update on the progress of Batten-1 MarketScreener

THERANEXUS : LYON NEUROSCIENCE RESEARCH CENTER AND CERMEP WIN THE '2024 RESEARCH PACT' PROJECT FOR THE AUVERGNE RHÔNE ALPES REGION - MarketScreener

THERANEXUS : LYON NEUROSCIENCE RESEARCH CENTER AND CERMEP WIN THE '2024 RESEARCH PACT' PROJECT FOR THE AUVERGNE RHÔNE ALPES REGION MarketScreener

THERANEXUS : LYON NEUROSCIENCE RESEARCH CENTER AND CERMEP WIN THE "2024 RESEARCH PACT" PROJECT FOR THE AUVERGNE RHÔNE ALPES REGION - MarketScreener

THERANEXUS : LYON NEUROSCIENCE RESEARCH CENTER AND CERMEP WIN THE "2024 RESEARCH PACT" PROJECT FOR THE AUVERGNE RHÔNE ALPES REGION MarketScreener

English Portal - Theranexus, treatment for rare neurological diseases - cea.fr

English Portal - Theranexus, treatment for rare neurological diseases cea.fr

Theranexus : THERANEXUS PUBLISHES ITS CASH POSITION AS OF 31 DECEMBER 2023 AND PRESENTS AN UPDATE ON ITS PROGRAMS - MarketScreener

Theranexus : THERANEXUS PUBLISHES ITS CASH POSITION AS OF 31 DECEMBER 2023 AND PRESENTS AN UPDATE ON ITS PROGRAMS MarketScreener

Theranexus : THERANEXUS PUBLISHES ITS CASH POSITION AS OF 30 SEPTEMBER 2023 - MarketScreener

Theranexus : THERANEXUS PUBLISHES ITS CASH POSITION AS OF 30 SEPTEMBER 2023 MarketScreener

Theranexus : THERANEXUS PUBLISHES ITS CASH POSITION AS OF 31 DECEMBER 2022 AND ANNOUNCES ORGANIZATIONAL CHANGES - MarketScreener

Theranexus : THERANEXUS PUBLISHES ITS CASH POSITION AS OF 31 DECEMBER 2022 AND ANNOUNCES ORGANIZATIONAL CHANGES MarketScreener

Theranexus : AISTROSIGHT - MarketScreener

Theranexus : AISTROSIGHT MarketScreener

THERANEXUS AND BBDF OBTAIN ORPHAN DRUG DESIGNATION (ODD) AND RARE PEDIATRIC DISEASE DESIGNATION (RPDD) FROM… - Actusnews

THERANEXUS AND BBDF OBTAIN ORPHAN DRUG DESIGNATION (ODD) AND RARE PEDIATRIC DISEASE DESIGNATION (RPDD) FROM… Actusnews

Top Theranexus Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant